2026-04-16 from ctvnews.ca
PARIS, France -- Drugs once hailed as a breakthrough in the fight against Alzheimer’s disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.
The review by the Cochrane organization -- which is considered the gold standard for analyzing existing evidence -- looked at drugs that target a plaque called amyloids which builds up in the brains of Alzheimer’s patients.
Researchers have long sought a way to eliminate this plaque, believing it could be the cause of the most common form of dementia which affects millions of elderly people every year.
After decades of costly yet unsuccessful research, two anti-amyloid drugs called lecanemab and donanemab were initially hailed as gamechangers that finally offered a way to slow the progress of the debilitating disease.
Read more here